| Viral Indicators | COVID-19, SARS, H1N1, MERS and Ebola, Influenza, Hepatitis B and C |
| Bacterial Indicators | Expertise in multi drug-resistant infections as clA, cUTl, HAP/VAP, ABSSI, joint infections, osteomyelitis. |
| |
| In-Vitro Antimicrobial studies | MIC assays (minimum inhibitory concentration) |
| MBC assays (minimum bactericidal concentration) |
| Time-kill assays |
| In Vitro pharmacokinetic and pharmacodynamics assays |
| Resistance testing |
| Cell-based assays (internalization and killing and biofilm assays) |
| Immune modulation assays (ELISA, Luminex, and FACS) |
| Metagenomics |
| |
| In Vitro Anti-Viral studies | COVID-19 protease inhibition assay |
| TCID50 assay |
| EC50 /CC50 assay |
| Plaque assays |
| HAI assays (hemagglutination inhibition) |
| Metagenomics |
| |
| Gastrointestinal Disorders | Ascites |
| Biliary Duct Stenosis |
| Colorectal Conditions |
| Constipation |
| Crohn’s Disease |
| Liver Cirrhosis |
| Exocrine pancreatic insufficiency in cystic fibrosis |
| GERD |
| Intestinal transit modulation |
| Inflammatory Bowel Disease |
| Irritable Bowel Disease |
| Gastroenteritis Infections |
| Pancreatic cancer |
| Ulcerative Colitis |
| Miscellaneous based on customers requirement subject to Feasibility |
